Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury (Duloxetine)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01223001 |
Recruitment Status
:
Terminated
(Most potential subjects had already been prescribed Cymbalta.)
First Posted
: October 18, 2010
Results First Posted
: December 17, 2014
Last Update Posted
: December 17, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Traumatic Brain Injury Depression | Drug: Duloxetine Drug: Sugar pill | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 8 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Prevention of Depression and Enhancement of Cognitive Recovery Following Traumatic Brain Injury With Duloxetine |
Study Start Date : | September 1996 |
Actual Primary Completion Date : | July 2011 |
Actual Study Completion Date : | July 2011 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Duloxetine
Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
|
Drug: Duloxetine
Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
Other Name: Cymbalta
|
Placebo Comparator: Sugar pill
Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
|
Drug: Sugar pill
Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
Other Name: Lactose
|
- Hamilton Rating Scale for Depression [ Time Frame: 9 months ]To compare the efficacy of duloxetine 30 mg. PO daily to 120mg. PO daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury, utilizing the Hamilton Rating Scale for Depression (Hamilton, 1960; HAM-D) as the primary efficacy measure.
- Hopkins Verbal Learning Test [ Time Frame: 9 months ]To compare the effect of duloxetine vs. placebo on the recovery of memory functions of patients with traumatic brain injury, utilizing the 20-minute delayed recall score of the Hopkins Verbal Learning Test (Brandt, 1991) as the secondary efficacy measure.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Study participants will be 40 men and women between the ages of 18 and 75 who provide appropriate consent and who are agreeable to study requirements
- Diagnosed with mild to moderate traumatic brain injury as defined by an initial Mayo Traumatic Brain Injury Severity Scale
- Have memory impairments defined by a Hopkins Verbal Learning Test delayed recall score which falls less than or equal to 1.5 standard deviation below the mean.
Exclusion Criteria:
- Refusal to give informed consent
- A previous Central Nervous System illness or injury, including seizure that exhibits residual symptoms.
- Current post-traumatic seizure disorder
- A previous diagnosis of a psychotic disorder
- Current or previous (in the last 6 months) treatment history for alcohol or substance dependency
- Medications affecting noradrenergic or dopaminergic systems, alpha-adrenergic antihypertensives, antidepressant, phenobarbital, Monoamine oxidase inhibitor (MAOI), scheduled benzodiazepines, psychoactive herbal supplements (including Kava, St. John's wort), or nutritional supplements or within at least 14 days of discontinuing treatment with the above medications or supplements.
- A known suicide risk
- A pregnant or breastfeeding woman
- Uncontrolled narrow-angle glaucoma
- Serious and/or unstable medical comorbidity (e.g., AIDS, cancer, history of uncontrolled hypertension or cardiovascular disease) psychological condition, or clinically significant laboratory abnormality that in the opinion of the investigator would compromise participation in the study or be likely to lead to hospitalization during the course of the study
- Liver enzymes > 1.5 times upper limit of normal
- Patients with end-stage renal disease (requiring dialysis) or severe renal impairment
- Known hypersensitivity to duloxetine or any of the inactive ingredients

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01223001
United States, Indiana | |
Rehabilitation Hospital of Indiana | |
Indianapolis, Indiana, United States, 46254 |
Principal Investigator: | Lance Trexler, Ph.D. | Rehabilitation Hospital of Indiana |
Responsible Party: | Rehabilitation Hospital of Indiana |
ClinicalTrials.gov Identifier: | NCT01223001 History of Changes |
Other Study ID Numbers: |
RHI 05-096 F1J-US-X025 ( Other Identifier: Eli Lilly and Co. ) |
First Posted: | October 18, 2010 Key Record Dates |
Results First Posted: | December 17, 2014 |
Last Update Posted: | December 17, 2014 |
Last Verified: | November 2014 |
Keywords provided by Rehabilitation Hospital of Indiana:
Depression Traumatic brain injury Duloxetine Cymbalta impaired cognitive function |
Additional relevant MeSH terms:
Wounds and Injuries Brain Injuries Brain Injuries, Traumatic Brain Diseases Craniocerebral Trauma Trauma, Nervous System Depression Depressive Disorder Behavioral Symptoms Mood Disorders Mental Disorders Central Nervous System Diseases Nervous System Diseases |
Duloxetine Hydrochloride Serotonin and Noradrenaline Reuptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents Antidepressive Agents Psychotropic Drugs Dopamine Agents |